Table 1.
Change from baseline in HbA1c (%) to Week 26
| Placebo (n = 161) | Metformin (n = 161) | Alogliptin (n = 162) | Alogliptin + metformin (n = 158) | |
|---|---|---|---|---|
| Baseline | ||||
| n | 161 | 161 | 162 | 158 |
| Mean (SD) | 8.21 (0.77) | 8.40 (0.77) | 8.48 (0.71) | 8.39 (0.81) |
| Change from baseline to Week 26, Model 1 1 | ||||
| n | 157 | 160 | 160 | 158 |
| LS mean (SE) | −0.19 | −1.04 (0.11) | −0.86 (0.11) | −1.53 |
| LS mean difference 2 | −0.49 | −0.68 | ||
| 95% CI | −0.700, −0.278 | −0.889, −0.467 | ||
| P‐value vs alogliptin + metformin | <0.0001 | <0.0001 | ||
| Change from baseline to Week 26, Model 2 3 | ||||
| N | 157 | 160 | 160 | 158 |
| LS mean (SE) | −0.17 | −1.17 (0.22) | −0.74 (0.22) | −1.53 |
| LS mean difference 2 | −0.36 | −0.78 | ||
| 95% CI | −0.793, 0.073 | −1.213, −0.353 | ||
| P‐value vs alogliptin + metformin | 0.103 | <0.001 |
Abbreviations: CI, confidence interval; HbA1c, haemoglobin A1c; LS, least‐squares; SD, standard deviation; SE, standard error.
1
Covariates were treatment, country, baseline HbA1c.
2
Vs alogliptin + metformin.
3
Covariates were treatment, country, baseline HbA1c, treatment by baseline HbA1c and treatment by country interaction.